On July 8, 2025, Galectin Therapeutics Inc. secured a line of credit of up to $10 million from Richard E. Uihlein to support working capital needs, with borrowing available until April 30, 2026, at an interest rate of 6.05%. Additionally, they approved bonuses for employees contingent on partnership agreements and announced a retention bonus for key executives.